Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma

Authors

Craig A Portell, University of Virginia
Nolan A Wages, University of Virginia
Brad S Kahl, Washington University School of Medicine in St. Louis
Lihua E Budde, City of Hope National Medical Center
Robert W Chen, City of Hope National Medical Center
Jonathon B Cohen, Emory University
Nikole E Varhegyi, University of Virginia
Gina R Petroni, University of Virginia
Michael E Williams, University of Virginia

Journal

Blood Advances

Publication Date

3-8-2022

Volume

6

Issue

5

First Page

1490

Last Page

1498

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2021005357

Rights and Permissions

Portell CA, Wages NA, Kahl BS, Budde LE, Chen RW, Cohen JB, Varhegyi NE, Petroni GR, Williams ME. Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma. Blood Adv. 2022 Mar 8;6(5):1490-1498. doi.org/10.1182/bloodadvances.2021005357 © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Recommended Citation

Portell, Craig A; Wages, Nolan A; Kahl, Brad S; Budde, Lihua E; Chen, Robert W; Cohen, Jonathon B; Varhegyi, Nikole E; Petroni, Gina R; and Williams, Michael E, "Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma." Blood Advances. 6, 5. 1490 - 1498. (2022).
https://digitalcommons.wustl.edu/open_access_pubs/11789